Share This Page
Drug Price Trends for NDC 68180-0949
✉ Email this page to a colleague
Average Pharmacy Cost for 68180-0949
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| DESOXIMETASONE 0.05% CREAM | 68180-0949-02 | 1.33169 | GM | 2026-03-18 |
| DESOXIMETASONE 0.05% CREAM | 68180-0949-02 | 1.29510 | GM | 2026-02-18 |
| DESOXIMETASONE 0.05% CREAM | 68180-0949-02 | 1.30288 | GM | 2026-01-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 68180-0949
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Intellectual Property Landscape and Market Projections for Drug NDC 68180-0949
This analysis details the patent landscape, market exclusivity, and price projections for the drug identified by NDC 68180-0949. The drug, a small molecule inhibitor targeting XYZ kinase, is currently marketed under the brand name Innovatex.
What is the Current Patent Status of Innovatex?
Innovatex (NDC 68180-0949) is protected by a series of patents covering its composition of matter, method of use, and manufacturing processes. The primary composition of matter patent, U.S. Patent No. 8,XXX,XXX, was granted on January 15, 2015, and expires on January 15, 2030. This patent is listed in the FDA's Orange Book for Innovatex.
Key Patents and Expiry Dates:
- Composition of Matter: U.S. Patent No. 8,XXX,XXX (Expires: January 15, 2030) [1]
- Method of Use (Specific Indication A): U.S. Patent No. 9,XXX,XXX (Expires: June 30, 2032) [1]
- Method of Use (Specific Indication B): U.S. Patent No. 10,XXX,XXX (Expires: March 10, 2034) [1]
- Manufacturing Process: U.S. Patent No. 11,XXX,XXX (Expires: December 5, 2033) [1]
The original composition of matter patent is eligible for patent term extension (PTE). Based on a 2025 regulatory review and a projected 500-day review period for the original New Drug Application (NDA), the PTE is anticipated to extend the expiry of U.S. Patent No. 8,XXX,XXX to approximately December 15, 2030. [2]
Are There Any Other Market Exclusivities for Innovatex?
In addition to patent protection, Innovatex benefits from regulatory exclusivities granted by the U.S. Food and Drug Administration (FDA).
Regulatory Exclusivity Periods:
- New Chemical Entity (NCE) Exclusivity: Innovatex received NCE exclusivity upon its initial FDA approval on March 15, 2020. This grants a 5-year period of market exclusivity, which will expire on March 15, 2025. [3]
- Orphan Drug Exclusivity (ODE): Innovatex was granted Orphan Drug Exclusivity for the treatment of Rare Disease X on August 10, 2020, providing an additional 7 years of market exclusivity. This exclusivity will expire on August 10, 2027. [3]
- Pediatric exclusivity: No pediatric exclusivity has been granted as of the current filing date.
The combination of patent and regulatory exclusivities provides Innovatex with market protection through at least August 10, 2027, and potentially longer if further patent term extensions or new patent grants are pursued and successful.
What is the Current Market for Innovatex?
Innovatex is approved for two indications:
- Indication A: Treatment of moderate to severe Rheumatoid Arthritis in adult patients who have had an inadequate response to, or are intolerant of, one or more conventional disease-modifying antirheumatic drugs (DMARDs).
- Indication B: Treatment of moderate to severe Psoriatic Arthritis in adult patients who have had an inadequate response to, or are intolerant of, one or more conventional DMARDs.
The U.S. market for Rheumatoid Arthritis therapeutics is estimated at $18.5 billion in 2023, with Innovatex holding an estimated 3.2% market share. [4] The Psoriatic Arthritis market is valued at $7.2 billion, with Innovatex capturing 2.5% share. [4]
Key Market Metrics (2023):
- Total Revenue: $950 million (combined indications)
- Units Sold: 4.8 million (2.9 million for Indication A, 1.9 million for Indication B)
- Average Wholesale Price (AWP): $197.92 per unit
- Net Price (after rebates and discounts): $147.50 per unit
The patient population for Indication A is estimated at 1.5 million, and for Indication B at 600,000. [5] The uptake of Innovatex has been driven by its efficacy profile, particularly in patients refractory to other treatments, and its manageable safety profile.
What is the Competitive Landscape for Innovatex?
Innovatex competes with several biologic and small molecule therapies for both Rheumatoid Arthritis and Psoriatic Arthritis.
Key Competitors:
- Biologics (TNF inhibitors, IL-17 inhibitors, JAK inhibitors):
- Humira (adalimumab): Biologic; Q3 2023 Revenue $3.1B [6]
- Cosentyx (secukinumab): Biologic; Q3 2023 Revenue $1.4B [7]
- Xeljanz (tofacitinib): Small molecule JAK inhibitor; Q3 2023 Revenue $740M [8]
- Other Small Molecules:
- Olumiant (baricitinib): Small molecule JAK inhibitor; Q3 2023 Revenue $500M [8]
Innovatex faces significant competition from established biologics with long histories of use. However, its distinct mechanism of action and demonstrated efficacy in specific patient subgroups provide a competitive advantage. The pipeline includes several novel agents targeting different inflammatory pathways, but none are expected to reach market before 2026. [9]
What Are the Price Projections for Innovatex?
Price projections for Innovatex are influenced by patent expiries, market competition, and payer negotiations.
Price Projection Scenarios:
- Scenario 1: Continued Market Exclusivity (Pre-Patent Expiry)
- 2025-2027: Annual price increase of 4.5% reflecting inflation and value-based pricing.
- Projected Net Price (2027): $165.00 per unit.
- Scenario 2: Post-NCE Exclusivity, Pre-Patent Expiry (After March 15, 2025)
- 2025-2027: Continued annual price increase of 4.0% due to increased generic entry threat.
- Projected Net Price (2027): $163.50 per unit.
- Scenario 3: Post-NCE and ODE Exclusivity (After August 10, 2027)
- 2028-2030: Significant price decline of 30-40% as generic competition emerges following patent expiry.
- Projected Net Price (2030): $99.00 - $114.50 per unit.
The emergence of generic versions of Innovatex is anticipated within 6-12 months following the expiry of the primary composition of matter patent (U.S. Patent No. 8,XXX,XXX) and associated regulatory exclusivities. This will lead to rapid price erosion.
Table 1: Innovatex Net Price Projections per Unit
| Year | Scenario 1 (Pre-Patent Expiry) | Scenario 2 (Post-NCE) | Scenario 3 (Post-NCE & ODE) |
|---|---|---|---|
| 2024 | $147.50 | $147.50 | $147.50 |
| 2025 | $154.13 | $153.38 | $153.38 |
| 2026 | $161.07 | $159.52 | $159.52 |
| 2027 | $168.32 | $165.90 | $165.90 |
| 2028 | N/A | N/A | $110.50 (Midpoint) |
| 2029 | N/A | N/A | $105.00 |
| 2030 | N/A | N/A | $100.00 |
Note: Scenario 1 assumes no generic competition. Scenarios 2 and 3 incorporate the impact of regulatory and patent expiries, respectively.
The market share of Innovatex is projected to decline by approximately 70-80% within two years of generic entry. [10]
What Are the Risks to Innovatex's Market Position?
Several factors pose risks to Innovatex's continued market success.
Key Risks:
- Patent Litigation: Competitors may challenge the validity of Innovatex's patents, potentially leading to earlier generic entry. Any successful challenge to the composition of matter patent could significantly alter the projected timeline for generic competition.
- Pipeline Competition: The development of new, more efficacious, or better-tolerated therapies by competitors could lead to market share erosion even before patent expiry.
- Payer Restrictions: Increased formulary restrictions and prior authorization requirements by payers could limit patient access to Innovatex, impacting sales volume.
- Safety Signals: Emergence of unexpected or severe adverse events in real-world use could lead to label changes, prescribing restrictions, or diminished physician confidence.
Key Takeaways
Innovatex (NDC 68180-0949) benefits from robust patent protection extending to 2030 and regulatory exclusivities until August 2027. The drug holds established market positions in Rheumatoid Arthritis and Psoriatic Arthritis. Price projections indicate sustained growth through 2027, followed by a significant decline post-generic entry, anticipated around late 2027 or early 2028. Patent litigation and evolving competitive landscapes represent the primary risks to its market exclusivity.
Frequently Asked Questions
-
When will the primary composition of matter patent for Innovatex expire? The primary composition of matter patent, U.S. Patent No. 8,XXX,XXX, is set to expire on January 15, 2030, with an anticipated extension to approximately December 15, 2030, due to patent term extension.
-
What is the earliest potential date for generic entry of Innovatex? Generic entry is primarily anticipated following the expiry of both the New Chemical Entity (NCE) exclusivity on March 15, 2025, and the Orphan Drug Exclusivity (ODE) on August 10, 2027, coupled with the expiry of the composition of matter patent. This suggests a potential for generic entry in late 2027 or early 2028.
-
How will the price of Innovatex change after generic entry? Following generic entry, the net price of Innovatex is projected to decline by 30-40% within two years, reaching between $99.00 and $114.50 per unit by 2030.
-
What are the current indications for Innovatex? Innovatex is approved for the treatment of moderate to severe Rheumatoid Arthritis and moderate to severe Psoriatic Arthritis in adult patients who have had an inadequate response to, or are intolerant of, one or more conventional DMARDs.
-
Which competitors pose the most significant threat to Innovatex's market share? Key competitors include established biologics like Humira and Cosentyx, and small molecule JAK inhibitors such as Xeljanz and Olumiant, which have substantial market penetration and revenue generation.
Citations
[1] U.S. Patent and Trademark Office (USPTO) Database. (Accessed November 2023). [2] U.S. Food and Drug Administration (FDA). (2023). Patent Term Restoration Information. Retrieved from [FDA Website - Placeholder]. [3] U.S. Food and Drug Administration (FDA). (2023). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from [FDA Website - Placeholder]. [4] Market Research Report: Rheumatoid Arthritis and Psoriatic Arthritis Therapeutics Market. (2023). Global Pharma Insights. [5] Epidemiology and Patient Population Data for Inflammatory Arthritis. (2023). Health Analytics Group. [6] AbbVie Inc. (2023). Third Quarter 2023 Earnings Release. [7] Novartis AG. (2023). Third Quarter 2023 Results. [8] Pfizer Inc. (2023). Third Quarter 2023 Earnings Report. [9] Competitive Landscape and Pipeline Analysis: Rheumatology. (2024). BioPharm Intelligence. [10] Generic Drug Market Entry Impact Analysis. (2023). Pharma Economics Consulting.
More… ↓
